Abnormally elevated RUNX1 levels in prostate cancer promote the EMT phenotype and activate the Akt/P38/JNK-MAPK signaling pathway driving the invasion and metastasis of prostate cancer cells [46]. Here, RUNX1 is linked to prostate carcinoma.